...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >A Novel Korean Red Ginseng Compound Gintonin Inhibited Inflammation by MAPK and NF-κB Pathways and Recovered the Levels of mir-34a and mir-93 in RAW 264.7 Cells
【24h】

A Novel Korean Red Ginseng Compound Gintonin Inhibited Inflammation by MAPK and NF-κB Pathways and Recovered the Levels of mir-34a and mir-93 in RAW 264.7 Cells

机译:新型韩国红参复合人参皂苷抑制MAPK和NF-κB途径引起的炎症反应,并恢复RAW 264.7细胞中mir-34a和mir-93的水平

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The beneficial health promoting effects of ginseng from vitalizing the body to enhancing long life have been well explored very rapidly in the past few years. Up till now many ginsenosides have been discovered for their marvelous therapeutic effects. However during past three years, a novel ginseng compound has been discovered, called gintonin, that differs from other ginsenosides on the basis of its signal transduction and chemical nature. Gintonin has been widely studied for its anti-Alzheimer’s disease activities and other neuropathies. However, its anti-inflammatory activity remained unexplored. In our study we have reported for the first time the anti-inflammatory activity of gintonin on RAW 264.7 cells. We found that gintonin potently suppresses the nitric oxide production without any cytotoxicity at given doses and also efficiently suppressed the levels of proinflammatory cytokines. Moreover, it mediaes its signal transduction via MAPK and NF-κB pathways and revives the levels of mir-34a and mir-93. These findings are valuable for the anti-inflammatory effects of this new compound with particular reference to microRNA involvement in the ginseng family.
机译:在过去的几年中,人参从活化人体到延长寿命的有益健康促进作用已经得到了很好的研究。迄今为止,已发现许多人参皂甙具有奇妙的治疗效果。然而,在过去的三年中,发现了一种新型人参化合物,称为人参皂苷,其信号传导和化学性质与其他人参皂苷不同。金丁宁因其抗阿尔茨海默氏病和其他神经病的作用而被广泛研究。然而,其抗炎活性仍未开发。在我们的研究中,我们首次报道了金精素对RAW 264.7细胞的抗炎活性。我们发现,在给定的剂量下,gintinin可以有效地抑制一氧化氮的产生而没有任何细胞毒性,并且还可以有效地抑制促炎细胞因子的水平。此外,它通过MAPK和NF-κB途径介导其信号转导,并恢复mir-34a和mir-93的水平。这些发现对于这种新化合物的抗炎作用是有价值的,特别是涉及人参家族中的微小RNA。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号